MA28991B1 - Procede pour concentrer des anticorps, et produits therapeutiques correspondants - Google Patents

Procede pour concentrer des anticorps, et produits therapeutiques correspondants

Info

Publication number
MA28991B1
MA28991B1 MA29809A MA29809A MA28991B1 MA 28991 B1 MA28991 B1 MA 28991B1 MA 29809 A MA29809 A MA 29809A MA 29809 A MA29809 A MA 29809A MA 28991 B1 MA28991 B1 MA 28991B1
Authority
MA
Morocco
Prior art keywords
therapeutic products
corresponding therapeutic
concentrating
antibodies
concentrating antibodies
Prior art date
Application number
MA29809A
Other languages
English (en)
Inventor
Charles Matthew Winter
Original Assignee
Genentech Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28991(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Novartis Ag filed Critical Genentech Inc
Publication of MA28991B1 publication Critical patent/MA28991B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
MA29809A 2004-09-09 2007-04-06 Procede pour concentrer des anticorps, et produits therapeutiques correspondants MA28991B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof

Publications (1)

Publication Number Publication Date
MA28991B1 true MA28991B1 (fr) 2007-11-01

Family

ID=35996499

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29809A MA28991B1 (fr) 2004-09-09 2007-04-06 Procede pour concentrer des anticorps, et produits therapeutiques correspondants

Country Status (33)

Country Link
US (6) US20060051347A1 (fr)
EP (5) EP2292636B9 (fr)
JP (2) JP5210633B2 (fr)
KR (2) KR101528970B1 (fr)
CN (3) CN104961797B (fr)
AR (1) AR050641A1 (fr)
AU (1) AU2005285243C1 (fr)
BR (1) BRPI0515649B8 (fr)
CA (1) CA2577317C (fr)
DK (5) DK1786830T3 (fr)
EC (1) ECSP077282A (fr)
ES (4) ES2942574T3 (fr)
FI (4) FI2292636T3 (fr)
GT (1) GT200500254A (fr)
HK (2) HK1101249A1 (fr)
HU (2) HUE061899T2 (fr)
IL (2) IL181372A (fr)
LT (4) LT3805248T (fr)
MA (1) MA28991B1 (fr)
MX (2) MX342788B (fr)
MY (2) MY150549A (fr)
NO (1) NO333660B1 (fr)
NZ (1) NZ553239A (fr)
PE (1) PE20060816A1 (fr)
PL (5) PL1786830T3 (fr)
PT (5) PT1786830E (fr)
RU (1) RU2390524C2 (fr)
SG (1) SG177161A1 (fr)
SI (5) SI4104859T1 (fr)
TN (1) TNSN07069A1 (fr)
TW (1) TWI372630B (fr)
WO (1) WO2006031560A2 (fr)
ZA (1) ZA200701626B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
SI1324776T2 (en) * 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
AU2005209360B2 (en) 2004-01-30 2009-06-25 Takeda Pharmaceutical Company Limited Production and purification of recombinant arylsulfatase A
DK1765294T3 (da) 2004-05-12 2008-11-10 Baxter Int Nukleinsyremikrokugler samt deres fremstilling og afgivelse
US7884085B2 (en) 2004-05-12 2011-02-08 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
KR20080031684A (ko) 2005-06-14 2008-04-10 암젠 인코포레이티드 자가 - 완충성 단백질 제형
DK2007506T3 (da) * 2006-03-31 2014-06-16 Danisco Us Inc Tangentialstrømningsfiltreringsapparater, -systemer og -fremgangsmådertil separering af forbindelser
SI2628746T1 (sl) 2006-04-04 2019-04-30 Chiesi Farmaceutici S.P.A. Proces za koncentriranje polipeptida
CA2681752A1 (fr) 2007-03-29 2008-10-09 Abbott Laboratories Anticorps anti-1l-12 humains cristallins
CN101754977B (zh) * 2007-07-17 2013-07-17 弗·哈夫曼-拉罗切有限公司 可变切向流过滤
CA2706403A1 (fr) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Agregats d'immunoglobulines
US8883146B2 (en) * 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2707483A1 (fr) * 2007-11-30 2009-06-11 Wolfgang Fraunhofer Formulations de proteine et leurs procedes de fabrication
PL2271382T3 (pl) 2008-04-15 2013-08-30 Grifols Therapeutics Inc Dwuetapowa ultrafiltracja/diafiltracja
EP2280999B1 (fr) * 2008-05-15 2017-09-06 Biosys Health Inc. Processus de production de fractions de lait riches en immunoglobulines de sécrétion
WO2010066634A1 (fr) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Procédé d'obtention d'une solution d'anticorps exempte d'excipient
WO2010090864A2 (fr) * 2009-01-21 2010-08-12 Smartflow Technologies, Inc. Optimisation de la séparation pour des suspensions visqueuses
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
EP2411125B1 (fr) * 2009-03-24 2019-05-08 Wyeth LLC Evaporation à travers une membrane pour la génération de produits thérapeutiques protéiques très concentrés
SG176256A1 (en) * 2009-05-27 2012-01-30 Baxter Int A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
WO2011039012A1 (fr) 2009-09-29 2011-04-07 F. Hoffmann-La Roche Ag Réglage de filtration préalable de solutés issus de tampon
LT2483305T (lt) * 2009-10-01 2016-11-25 F.Hoffmann-La Roche Ag Daugiakopis galutinis imunoglobulino filtravimas
CA2788863C (fr) 2010-02-04 2020-07-07 Reinhard Franz Bolli Preparation d'immunoglobuline
BR112012022258A2 (pt) 2010-03-01 2016-10-25 Bayer Healthcare Llc anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
WO2013009686A2 (fr) 2011-07-08 2013-01-17 Shire Human Genetic Therapies, Inc. Procédés de purification d'arylsulfatase a
SG11201400260TA (en) * 2011-09-01 2014-03-28 Chugai Pharmaceutical Co Ltd Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP2016504344A (ja) * 2012-12-28 2016-02-12 ノヴォ ノルディスク アー／エス 高温デッドエンド抗体ろ過
MX2015008875A (es) 2013-01-09 2015-10-22 Shire Human Genetic Therapies Metodos para la purificacion de arilsulfatasa a.
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
CA3140009C (fr) 2014-05-13 2023-09-05 Amgen Inc. Systemes et procedes de regulation de procedes destines a etre utilises avec des filtres et procedes de filtration
US10550148B2 (en) 2014-06-16 2020-02-04 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
WO2015195452A2 (fr) * 2014-06-16 2015-12-23 Emd Millipore Corporation Systèmes et procédés de filtration à simple passage
EP2957335B1 (fr) * 2014-06-16 2020-05-27 EMD Millipore Corporation Systèmes et processus de filtration monopasse
EP4144434B1 (fr) * 2014-06-16 2024-04-17 EMD Millipore Corporation Systèmes et procédés de filtration à passage unique
US10399039B2 (en) 2014-06-25 2019-09-03 Emd Millipore Corporation Compact spiral-wound filter elements, modules and systems
CN105592913B (zh) 2014-08-29 2018-04-03 Emd 密理博公司 用于使用单程切向流过滤系统和具有渗余物的再循环的切向流过滤系统过滤液体的方法
KR102188947B1 (ko) 2014-08-29 2020-12-09 이엠디 밀리포어 코포레이션 잔류물의 재순환을 이용한 싱글 패스 접선 유동 여과 시스템 및 접선 유동 여과 시스템
BR112017008125B1 (pt) 2014-10-23 2023-11-21 Amgen Inc. Método para a redução da viscosidade de formulações farmacêuticas, formulações farmacêuticas, método de preparação de um pó liofilizado, pó liofilizado e método para reconstituição de um pó liofilizado
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
KR20200035496A (ko) * 2015-09-22 2020-04-03 화이자 인코포레이티드 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
EP3500589B1 (fr) * 2016-08-16 2022-05-04 Genzyme Corporation Procédés de traitement d'un fluide comprenant une protéine thérapeutique recombinante et leur utilisation
JP7114567B2 (ja) * 2016-08-17 2022-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 生体分子を含む高濃縮液体製剤の調製のためのプロセス
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
WO2019132418A1 (fr) * 2017-12-27 2019-07-04 ㈜셀트리온 Procédé de diafiltration
BR112020020854A2 (pt) * 2018-04-12 2021-01-19 Amgen Inc. Métodos para produzir composições de proteínas estáveis
WO2019213567A1 (fr) * 2018-05-04 2019-11-07 Genzyme Corporation Bioréacteur de perfusion pourvu de systèmes de filtration
KR20210043607A (ko) * 2018-08-10 2021-04-21 암젠 인크 항체 제약 제형의 제조 방법
JP7483679B2 (ja) * 2018-08-14 2024-05-15 ブリストル－マイヤーズ スクイブ カンパニー 改善されたタンパク質の回収
TW202043253A (zh) * 2019-01-28 2020-12-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
DK3791395T3 (da) * 2019-07-31 2021-09-13 Catalent Uk Swindon Zydis Ltd Densitetsgennemstrømningsmåler til dosering af farmaceutisk formulering
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
JP2023544410A (ja) * 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
CA3199735A1 (fr) 2020-11-23 2022-05-27 Chris Klopp Systemes, composants et procedes de filtration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
IL314394A (en) 2022-02-25 2024-09-01 Amgen Inc Methods for preparing high-concentration liquid drug substances
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
WO2024012364A1 (fr) * 2022-07-12 2024-01-18 Beigene Switzerland Gmbh Procédés de préparation d'une solution d'anticorps pd1 hautement concentrée par ultrafiltration/diafiltration (uf/df)
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (fr) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IN161706B (fr) * 1983-10-05 1988-01-16 Solco Basel Ag
US4786501A (en) 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (fr) 1990-08-29 2005-07-27 GenPharm International, Inc. Souris transgéniques capables de produire des anticorps hétérologues
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU716785B2 (en) * 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
AU4589397A (en) * 1997-09-22 1999-04-12 Sepragen Corporation Sequential separation of whey proteins and formulations thereof
RU2140287C1 (ru) 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
WO2000024266A2 (fr) 1998-10-26 2000-05-04 Galagen, Inc. Compositions a base de soja et d'immunoglobulines
AR024676A1 (es) 1999-07-07 2002-10-23 New Zealand Co Operative Dairy Company Ltd Metodos para obtener aislados de proteina y concentrados de calostro
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
SI1324776T2 (en) * 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
EP1450847B1 (fr) * 2001-11-13 2010-09-29 Genentech, Inc. Compositions à base de APO2 ligand/TRAIL et leur utilisation
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
JP4500683B2 (ja) * 2002-11-01 2010-07-14 バイエル・ヘルスケア・エルエルシー 巨大分子濃縮方法
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
CN1759189A (zh) * 2003-02-24 2006-04-12 Gtc生物治疗学公司 切向流过滤方法及其装置
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法

Also Published As

Publication number Publication date
MX342788B (es) 2016-10-12
PT4104859T (pt) 2024-07-02
DK4104859T3 (da) 2024-07-08
WO2006031560A2 (fr) 2006-03-23
ES2942574T3 (es) 2023-06-02
KR20070109975A (ko) 2007-11-15
FI3805248T3 (fi) 2023-04-21
LT4104859T (lt) 2024-07-10
FI4108259T3 (fi) 2024-09-10
EP4108259B1 (fr) 2024-01-03
CA2577317C (fr) 2016-04-26
NO333660B1 (no) 2013-08-05
MY150549A (en) 2014-01-30
EP4104859B1 (fr) 2024-04-17
PT4108259T (pt) 2024-03-07
CN102911268A (zh) 2013-02-06
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
CN104961797A (zh) 2015-10-07
EP2292636B1 (fr) 2023-10-18
TW200612989A (en) 2006-05-01
EP4104859A1 (fr) 2022-12-21
KR101528970B9 (ko) 2022-12-09
CA2577317A1 (fr) 2006-03-23
LT3805248T (lt) 2023-04-25
TWI372630B (en) 2012-09-21
CN101056885B (zh) 2015-08-26
BRPI0515649A (pt) 2008-07-29
SI3805248T1 (sl) 2023-05-31
EP1786830B1 (fr) 2014-11-12
FI4104859T3 (fi) 2024-07-16
DK3805248T5 (da) 2023-04-24
SI4104859T1 (sl) 2024-08-30
EP2292636B9 (fr) 2024-01-03
KR101528970B1 (ko) 2015-06-15
SI1786830T1 (sl) 2015-03-31
EP4108259A1 (fr) 2022-12-28
HUE061899T2 (hu) 2023-08-28
US10370456B2 (en) 2019-08-06
PL4108259T3 (pl) 2024-05-13
EP2292636A3 (fr) 2013-05-01
AU2005285243C1 (en) 2012-10-25
JP2008512473A (ja) 2008-04-24
ES2528541T3 (es) 2015-02-10
WO2006031560A3 (fr) 2006-08-24
SG177161A1 (en) 2012-01-30
US20060051347A1 (en) 2006-03-09
BRPI0515649B1 (pt) 2021-10-13
FI2292636T3 (fi) 2024-01-12
EP3805248A2 (fr) 2021-04-14
GT200500254A (es) 2006-08-02
BRPI0515649B8 (pt) 2021-11-03
ES2968070T3 (es) 2024-05-07
US20070237762A1 (en) 2007-10-11
MY162525A (en) 2017-06-15
KR20120135530A (ko) 2012-12-14
DK1786830T3 (en) 2015-01-19
US20230074486A1 (en) 2023-03-09
US20140370003A1 (en) 2014-12-18
NO20071432L (no) 2007-03-16
PL1786830T3 (pl) 2015-05-29
HUE065025T2 (hu) 2024-04-28
NZ553239A (en) 2009-11-27
EP2292636A2 (fr) 2011-03-09
DK3805248T3 (da) 2023-04-03
MX2007002812A (es) 2007-05-16
EP3805248B1 (fr) 2023-01-18
AR050641A1 (es) 2006-11-08
AU2005285243B2 (en) 2012-03-08
DK4108259T3 (da) 2024-03-11
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
JP5426641B2 (ja) 2014-02-26
EP3805248A3 (fr) 2021-07-14
SI4108259T1 (sl) 2024-04-30
TNSN07069A1 (en) 2008-06-02
CN101056885A (zh) 2007-10-17
LT4108259T (lt) 2024-04-10
ECSP077282A (es) 2007-03-29
RU2390524C2 (ru) 2010-05-27
US11767370B2 (en) 2023-09-26
ZA200701626B (en) 2008-10-29
PL4104859T3 (pl) 2024-08-26
AU2005285243A1 (en) 2006-03-23
ES2975166T3 (es) 2024-07-03
IL181372A (en) 2012-01-31
HK1101249A1 (en) 2007-10-12
PL3805248T3 (pl) 2023-05-22
SI2292636T1 (sl) 2024-02-29
PT1786830E (pt) 2015-02-05
US20090214522A1 (en) 2009-08-27
JP5210633B2 (ja) 2013-06-12
DK2292636T3 (da) 2024-01-15
EP1786830A2 (fr) 2007-05-23
JP2012097086A (ja) 2012-05-24
PE20060816A1 (es) 2006-09-02
CN104961797B (zh) 2020-12-25
HK1215869A1 (zh) 2016-09-23
PT3805248T (pt) 2023-04-05
PL2292636T3 (pl) 2024-03-11
IL216851A0 (en) 2012-01-31
IL181372A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
MA28991B1 (fr) Procede pour concentrer des anticorps, et produits therapeutiques correspondants
EP1839491A4 (fr) Produit laitier et procede pour le produire
FR2868414B1 (fr) Procede de production d'alpha-alumine particulaire et apha-alumine particulaire produite par ce procede
LT1928255T (lt) Pieno produktų gamybos būdas, tuo būdu gauti produktai ir jų panaudojimas
FR2944275B1 (fr) Procede pour la production de fluoroapatite, fluoroapatite et appareil d'adsorption
FR2920320B1 (fr) Procede pour la production de fluorapatite, fluorapatite et appareil d'adsorption.
FR2836015B1 (fr) Nouveau procede de fabrication de produits laitiers fermente
FR2869030B1 (fr) Procede de production d'alpha-alumine particulaire
HUP0402466A2 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process
HUP0402465A2 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main intermediates of the process
EP1771075A4 (fr) Produit laitier et procede de fabrication correspondant
FR2900029B1 (fr) Procede d'aromatisation de produits fromagers.
FR2869764B1 (fr) Complement nutrionnel liquide et procede de preparation de ce complement
FR2870680B1 (fr) Nouveaux produits de bonneterie et leur procede de production
NO20044969L (no) Fremgangsmate for fremstilling av fermentert produkt, og produkt fremstilt ved fremgangsmaten
NO20044967D0 (no) Fremgangsmate for fremstilling av bakteriekultur samt produkt fremstilt ved fremgangsmaten
FI20041103A0 (fi) Menetelmä, järjestelmä ja ohjelmistotuote henkilömatkustusprosessin hallitsemiseksi
FR2871801B1 (fr) Procede de preparation d'arylboronates cycliques
UA8004S (uk) Ємність для молочних продуктів
UA11043S (uk) Пляшка для рідких продуктів